01235 832023
Many people with MS who feel able to work aren’t getting the right support in the workplace. This is according to a new report published by the All Party Parliamentary Group (APPG) for MS.
This follows a year-long review into whether people with MS have the support they need to stay in, or get back into, work. Read on.
People living in countries further away from the equator develop symptoms of multiple sclerosis at an earlier age, research suggests.
Both genetic and environmental factors are believed to be to behind the development of multiple sclerosis (MS), with previous work revealing that prevalence of the disease is higher among those living further away from the equator – in other words, in locations with higher latitudes. Read on.
Below are the dates for the first six months of next year:
3 January
24 January
14 February
7 March
28 March
18 April
16 May
6 June
All dates are with appointments starting at 9am and the last appointment at 1pm for a 1.30pm finish.
Make sure you have an MS parking sticker on your car because security are going to start fining people who shouldn’t be in our parking bays.
Are you interested in attending a Mindfulness course at the centre?
If we have enough interest we will explore?
Please contact Sue and let her know.
A University of Portsmouth scientist has won almost £180,000 to fund research that could help develop treatments for multiple sclerosis (MS) patients.
Dr Sassan Hafizi, a senior lecturer in the School of Pharmacy and Biomedical Sciences, has been awarded £177,930 by the MS Society to investigate the potentially beneficial role of a molecule found in the nervous system. Read on.
Neurologists in the U.S. expect — or, at least, highly anticipate — that Ocrevus (ocrelizumab), being developed by Roche as a treatment for both relapsing and progressive multiple sclerosis (MS), will be approved by year’s end, and a sizable number plan on quickly prescribing it, according to a recent update by Spherix Global Insights in “RealTime Dynamix: Multiple Sclerosis,” a quarterly report based on responses from over 100 neurologists actively treating MS patients. Read on.
Proposed changes to the drug approval process mean NHS England will assess how much they can afford to pay for new drugs.
Under the plan, new drugs that are expected to cost the NHS more than £20 million a year would be subject to a ‘budget impact test’. Read on.